Abstract
Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before diagnosis are unknown, and for which existing treatments are of limited benefit. The National Heart, Lung, and Blood Institute convened a working group to develop specific recommendations for future IPF research. Inflammatory and immune processes are involved in IPF pathogenesis, and current therapeutic strategies are aimed at suppressing the inflammation. Recent data suggest that the molecular processes underlying the fibrogenesis may provide new opportunities for therapeutic intervention. Specific areas of future research recommended by the working group include studies to elucidate the etiology of IPF, to develop novel diagnostic techniques and molecular diagnostics, to establish a program for identification of molecular targets for IPF treatment and identification and generation of agonists or antagonists that inhibit fibrogenesis, to foster investigations that couple the use of new technologies (e.g., laser capture microdissection, microarrays, and mass spectroscopic analysis of proteins) with data from the human genome project, to establish a national consortium of Clinical Centers of Excellence to conduct coordinated clinical and laboratory studies of well-characterized patients and patient-derived materials, and to stimulate research to develop animal models of persistent and progressive pulmonary fibrosis for evaluation of new intervention approaches.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 236-246 |
| Number of pages | 11 |
| Journal | American journal of respiratory and critical care medicine |
| Volume | 166 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jul 15 2002 |
Fingerprint
Keywords
- Lung diseases, interstitial
- National Institutes of Health (United States)
- Pulmonary fibrosis
Cite this
Future research directions in idiopathic pulmonary fibrosis : Summary of a National Heart, Lung, and Blood Institute Working Group. / Crystal, Ronald G.; Bitterman, Peter B.; Mossman, Brooke; Schwarz, Marvin I.; Sheppard, Dean; Almasy, Laura; Chapman, Harold A.; Friedman, Scott L.; King, Talmadge E.; Leinwand, Leslie A.; Liotta, Lance; Martin, George R.; Schwartz, David A.; Schultz, Gregory S.; Wagner, Carston R.; Musson, Robert A.
In: American journal of respiratory and critical care medicine, Vol. 166, No. 2, 15.07.2002, p. 236-246.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Future research directions in idiopathic pulmonary fibrosis
T2 - Summary of a National Heart, Lung, and Blood Institute Working Group
AU - Crystal, Ronald G.
AU - Bitterman, Peter B.
AU - Mossman, Brooke
AU - Schwarz, Marvin I.
AU - Sheppard, Dean
AU - Almasy, Laura
AU - Chapman, Harold A.
AU - Friedman, Scott L.
AU - King, Talmadge E.
AU - Leinwand, Leslie A.
AU - Liotta, Lance
AU - Martin, George R.
AU - Schwartz, David A.
AU - Schultz, Gregory S.
AU - Wagner, Carston R.
AU - Musson, Robert A.
PY - 2002/7/15
Y1 - 2002/7/15
N2 - Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before diagnosis are unknown, and for which existing treatments are of limited benefit. The National Heart, Lung, and Blood Institute convened a working group to develop specific recommendations for future IPF research. Inflammatory and immune processes are involved in IPF pathogenesis, and current therapeutic strategies are aimed at suppressing the inflammation. Recent data suggest that the molecular processes underlying the fibrogenesis may provide new opportunities for therapeutic intervention. Specific areas of future research recommended by the working group include studies to elucidate the etiology of IPF, to develop novel diagnostic techniques and molecular diagnostics, to establish a program for identification of molecular targets for IPF treatment and identification and generation of agonists or antagonists that inhibit fibrogenesis, to foster investigations that couple the use of new technologies (e.g., laser capture microdissection, microarrays, and mass spectroscopic analysis of proteins) with data from the human genome project, to establish a national consortium of Clinical Centers of Excellence to conduct coordinated clinical and laboratory studies of well-characterized patients and patient-derived materials, and to stimulate research to develop animal models of persistent and progressive pulmonary fibrosis for evaluation of new intervention approaches.
AB - Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before diagnosis are unknown, and for which existing treatments are of limited benefit. The National Heart, Lung, and Blood Institute convened a working group to develop specific recommendations for future IPF research. Inflammatory and immune processes are involved in IPF pathogenesis, and current therapeutic strategies are aimed at suppressing the inflammation. Recent data suggest that the molecular processes underlying the fibrogenesis may provide new opportunities for therapeutic intervention. Specific areas of future research recommended by the working group include studies to elucidate the etiology of IPF, to develop novel diagnostic techniques and molecular diagnostics, to establish a program for identification of molecular targets for IPF treatment and identification and generation of agonists or antagonists that inhibit fibrogenesis, to foster investigations that couple the use of new technologies (e.g., laser capture microdissection, microarrays, and mass spectroscopic analysis of proteins) with data from the human genome project, to establish a national consortium of Clinical Centers of Excellence to conduct coordinated clinical and laboratory studies of well-characterized patients and patient-derived materials, and to stimulate research to develop animal models of persistent and progressive pulmonary fibrosis for evaluation of new intervention approaches.
KW - Lung diseases, interstitial
KW - National Institutes of Health (United States)
KW - Pulmonary fibrosis
UR - http://www.scopus.com/inward/record.url?scp=0037099443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037099443&partnerID=8YFLogxK
U2 - 10.1164/rccm.2201069
DO - 10.1164/rccm.2201069
M3 - Article
C2 - 12119236
AN - SCOPUS:0037099443
VL - 166
SP - 236
EP - 246
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 2
ER -